logo
Plus   Neg
Share
Email

J&J Gets Positive CHMP Opinion For Investigational Preventive Ebola Vaccine Regimen

Johnson & Johnson said that its Janssen Pharmaceutical Companies received a positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species.

Janssen is collaborating with the World Health Organization or WHO on vaccine pre-qualification to broaden access of its investigational Ebola vaccine regimen to those most in need and enable registration in African countries; European Commission approval of this regimen may help accelerate this process.

The most recent Ebola outbreak, which started in the Democratic Republic of the Congo in 2018 was the world's second worst on record. It has caused more than 3,000 cases and over 2,000 deaths - a mortality rate of 65 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk, chief executive of electric car maker Tesla, said its own battery cells, which are under development now, will not reach high-volume production until 2022. This delay can affect the Cybertruck, Semi, and Roadster programs. He also said the company intends to increase battery cell purchases from partners Panasonic, LG & CATL, and possibly other partners. U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test.
Follow RTT